This segment focuses on the development and commercialization of Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases (HIF-PH). Research and development activities include Phase III clinical trials for the treatment of anemia in chronic kidney disease (CKD) in various regions, including the United States, Europe, China, and Japan. The technology utilizes HIF-PH inhibition to stimulate erythropoiesis, addressing the underlying cause of anemia. Patient impact is significant, as Roxadustat aims to provide a new treatment option for CKD patients suffering from anemia. Market positioning is focused on providing an alternative to existing treatments. Future opportunities include expanding indications and geographic reach. Regulatory aspects involve securing approvals from various health authorities. Partnerships with companies like Astellas Pharma Inc. and AstraZeneca AB have been instrumental in the development and commercialization of Roxadustat.

This segment concentrates on the development of Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF). Research and development efforts are centered on Phase III clinical trials for idiopathic pulmonary fibrosis (IPF), pancreatic cancer, liver fibrosis, diabetic kidney disease, and Duchenne muscular dystrophy (DMD). The technology utilizes a monoclonal antibody to target and inhibit CTGF, a key mediator of fibrosis. The patient impact is aimed at slowing or reversing the progression of fibrotic diseases, improving patient outcomes, and potentially extending life expectancy. Market positioning involves addressing unmet needs in fibrotic diseases. Future opportunities include expanding the indications for Pamrevlumab and exploring combination therapies. Regulatory aspects involve obtaining approvals from regulatory bodies. This segment benefits from collaborations with various partners to advance clinical trials and commercialization efforts.